85/100 · Critical
Manufactured by Avyxa Pharma, LLC
High Safety Concerns with Cyclophosphamide Use
284,202 FDA adverse event reports analyzed
Last updated: 2026-05-12
CYCLOPHOSPHAMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Avyxa Pharma, LLC. Based on analysis of 284,202 FDA adverse event reports, CYCLOPHOSPHAMIDE has a safety score of 85 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for CYCLOPHOSPHAMIDE include OFF LABEL USE, FEBRILE NEUTROPENIA, NEUTROPENIA, DRUG INEFFECTIVE, PYREXIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CYCLOPHOSPHAMIDE.
Cyclophosphamide has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 284,202 adverse event reports for this medication, which is primarily manufactured by Avyxa Pharma, Llc.
The most commonly reported adverse events include Off Label Use, Febrile Neutropenia, Neutropenia. Of classified reports, 96.2% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Cyclophosphamide is associated with a high incidence of serious adverse reactions, including infections and hematological toxicity.
The drug is frequently reported to cause severe neutropenia and thrombocytopenia, indicating significant risk of life-threatening complications. There is a notable risk of disease progression and recurrence, suggesting the drug may not always achieve long-term remission.
Patients taking Cyclophosphamide should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Cyclophosphamide can interact with other drugs, particularly those affecting bone marrow function, leading to increased toxicity. Warnings include monitoring for interactions and adjusting dosages accordingly. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Cyclophosphamide received a safety concern score of 85/100 (high concern). This is based on a 96.2% serious event ratio across 168,881 classified reports. The score accounts for 284,202 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 74,263, Male: 62,143, Unknown: 1,336. The most frequently reported age groups are age 60 (2,827 reports), age 65 (2,741 reports), age 62 (2,668 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 168,881 classified reports for CYCLOPHOSPHAMIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Cyclophosphamide can interact with other drugs, particularly those affecting bone marrow function, leading to increased toxicity. Warnings include monitoring for interactions and adjusting dosages accordingly.
If you are taking Cyclophosphamide, here are important things to know. The most commonly reported side effects include off label use, febrile neutropenia, neutropenia, drug ineffective, pyrexia. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Monitor blood counts regularly to detect early signs of hematological toxicity. Be vigilant for signs of infection, such as fever or chills, and seek medical attention immediately. Discuss potential drug interactions with your healthcare provider to minimize risk. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA closely monitors cyclophosphamide reports, and regulatory actions may be taken based on emerging safety signals. Patients should report any adverse reactions promptly.
The FDA has received approximately 284,202 adverse event reports associated with Cyclophosphamide. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Cyclophosphamide include Off Label Use, Febrile Neutropenia, Neutropenia, Drug Ineffective, Pyrexia. By volume, the top reported reactions are: Off Label Use (15,422 reports), Febrile Neutropenia (13,977 reports), Neutropenia (10,160 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Cyclophosphamide.
Out of 168,881 classified reports, 162,467 (96.2%) were classified as serious and 6,414 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Cyclophosphamide break down by patient sex as follows: Female: 74,263, Male: 62,143, Unknown: 1,336. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Cyclophosphamide adverse events are: age 60: 2,827 reports, age 65: 2,741 reports, age 62: 2,668 reports, age 66: 2,666 reports, age 64: 2,606 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Cyclophosphamide adverse event reports is Avyxa Pharma, Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Cyclophosphamide include: Disease Progression, Pneumonia, Product Use In Unapproved Indication, Thrombocytopenia, Nausea. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Cyclophosphamide to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Cyclophosphamide has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Cyclophosphamide is associated with a high incidence of serious adverse reactions, including infections and hematological toxicity.
Key safety signals identified in Cyclophosphamide's adverse event data include: Frequent reports of febrile neutropenia and pneumonia highlight the risk of severe infections.. High incidence of hematological toxicity, including anemia and leukopenia, indicates significant risk to blood cell production.. Multiple reports of disease progression and recurrence suggest limited efficacy in some patients.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Cyclophosphamide can interact with other drugs, particularly those affecting bone marrow function, leading to increased toxicity. Warnings include monitoring for interactions and adjusting dosages accordingly. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Cyclophosphamide.
Monitor blood counts regularly to detect early signs of hematological toxicity. Be vigilant for signs of infection, such as fever or chills, and seek medical attention immediately. Discuss potential drug interactions with your healthcare provider to minimize risk.
Cyclophosphamide has 284,202 adverse event reports on file with the FDA. The drug is frequently reported to cause severe neutropenia and thrombocytopenia, indicating significant risk of life-threatening complications. The volume of reports for Cyclophosphamide reflects both the drug's usage level and the vigilance of the reporting community.
The FDA closely monitors cyclophosphamide reports, and regulatory actions may be taken based on emerging safety signals. Patients should report any adverse reactions promptly. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Avyxa Pharma, LLC and compare their safety profiles:
The following drugs share commonly reported adverse reactions with CYCLOPHOSPHAMIDE:
Drugs related to CYCLOPHOSPHAMIDE based on therapeutic use, drug class, or shared indications: